Yahoo
Swiss - Delayed Quote CHF

Kuros Biosciences AG (KURN.SW)

20.64 -0.20 (-0.96%)
At close: October 30 at 5:30:30 PM GMT+1
Chart Range Bar
Loading chart for KURN.SW
  • Previous Close 20.84
  • Open 20.90
  • Bid --
  • Ask --
  • Day's Range 20.64 - 21.30
  • 52 Week Range 16.46 - 32.48
  • Volume 134,845
  • Avg. Volume 228,264
  • Market Cap (intraday) 820.578M
  • Beta (5Y Monthly) 0.76
  • PE Ratio (TTM) 121.41
  • EPS (TTM) 0.17
  • Earnings Date Aug 13, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 34.33

Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Granules, an advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.

www.kurosbio.com

213

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

KURN.SW
24.89%
MSCI WORLD (^990100-USD-STRD)
9.06%

1-Year Return

KURN.SW
29.65%
MSCI WORLD (^990100-USD-STRD)
9.89%

3-Year Return

KURN.SW
703.11%
MSCI WORLD (^990100-USD-STRD)
0.00%

5-Year Return

KURN.SW
882.86%
MSCI WORLD (^990100-USD-STRD)
53.16%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue 35.01M
Earnings --
Profit Margin 0.00%

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

0
10M
20M
30M
0.0%

Analyst Insights

View More

Analyst Price Targets

32.00
34.33 Average
20.64 Current
38.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    5.13%

  • Return on Assets (ttm)

    5.13%

  • Return on Equity (ttm)

    10.73%

  • Revenue (ttm)

    174.93M

  • Net Income Avi to Common (ttm)

    8.9M

  • Diluted EPS (ttm)

    0.17

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    9.73M

  • Total Debt/Equity (mrq)

    11.28%

  • Levered Free Cash Flow (ttm)

    -9.36M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: